Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sarah Cannon Cancer Institute is the global cancer enterprise of HCA Healthcare, providing a comprehensive clinical trial network and integrated cancer care services. Founded in 1993, it has become a leader in drug development, having participated in clinical trials for the majority of cancer therapies approved by the FDA over the last decade. The institute offers specialized programs in areas such as cardiovascular research, molecular profiling, and personalized medicine. Through its extensive network in the United States and United Kingdom, Sarah Cannon connects patients to innovative treatments and advanced clinical research. In 2022, its research arm formed a significant joint venture with McKesson's US Oncology Research to further expand its clinical trial capabilities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sarah Cannon Cancer Institute.